Associated Papers
Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2023
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.
Soria-Chacartegui P et al.
Frontiers in Pharmacology, 2021
UGT2B10 Genotype Influences Serum Cotinine Levels and Is a Primary Determinant of Higher Cotinine in African American Smokers.
Sipe CJ et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2020
Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing.
Labriet A et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers.
Murphy SE et al.
Chemical Research in Toxicology, 2018
Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2.
Ware JJ et al.
Scientific Reports, 2016
A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure.
Fowler S et al.
The Journal of Pharmacology and Experimental Therapeutics, 2015
The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations.
Patel YM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2015
Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.
Murphy SE et al.
Carcinogenesis, 2014
The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
Bloom AJ et al.
Pharmacogenetics and Genomics, 2013
Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ et al.
Plos One, 2013
Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G et al.
Pharmacogenetics and Genomics, 2012
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.
Erickson-Ridout KK et al.
Pharmacogenetics and Genomics, 2011
UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
Berg JZ et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2010
Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
Berg JZ et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines.
Chen G et al.
Pharmacogenetics and Genomics, 2008